BLRX
Income statement / Annual
Last year (2024), BioLineRx Ltd.'s total revenue was $28.94 M,
an increase of 502.92% from the previous year.
In 2024, BioLineRx Ltd.'s net income was -$9.22 M.
See BioLineRx Ltd.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$28.94 M |
$4.80 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$9.26 M
|
$3.69 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$19.68 M
|
$1.11 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.68
|
0.23
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$9.15 M
|
$12.52 M
|
$17.63 M
|
$19.47 M
|
$18.17 M
|
$23.44 M
|
$19.81 M
|
$19.51 M
|
$11.18 M
|
$11.49 M
|
| General & Administrative Expenses |
$18.46 M
|
$16.64 M
|
$5.07 M
|
$4.27 M
|
$3.84 M
|
$3.74 M
|
$4.41 M
|
$4.04 M
|
$3.95 M
|
$3.65 M
|
| Selling & Marketing Expenses |
$10.08 M
|
$14.59 M
|
$6.46 M
|
$1.00 M
|
$840.00 K
|
$857.00 K
|
$1.36 M
|
$1.69 M
|
$1.35 M
|
$1.00 M
|
| Selling, General & Administrative Expenses |
$28.54 M
|
$31.23 M
|
$11.53 M
|
$5.27 M
|
$4.68 M
|
$4.60 M
|
$5.77 M
|
$5.73 M
|
$5.31 M
|
$4.65 M
|
| Other Expenses |
$2.40 M
|
$7.05 M
|
$0.00
|
$42.00 K
|
$70.00 K
|
$78.00 K
|
$27.00 K
|
$0.00
|
$30.00 K
|
$57.00 K
|
| Operating Expenses |
$40.09 M
|
$50.80 M
|
$29.16 M
|
$24.78 M
|
$22.93 M
|
$28.11 M
|
$25.61 M
|
$25.24 M
|
$16.51 M
|
$16.20 M
|
| Cost And Expenses |
$49.35 M
|
$54.49 M
|
$29.16 M
|
$24.78 M
|
$22.93 M
|
$28.11 M
|
$25.61 M
|
$25.24 M
|
$16.51 M
|
$16.20 M
|
| Interest Income |
$1.83 M
|
$2.01 M
|
$694.00 K
|
$559.00 K
|
$236.00 K
|
$777.00 K
|
$719.00 K
|
$1.17 M
|
$480.00 K
|
$457.00 K
|
| Interest Expense |
$9.16 M
|
$2.17 M
|
$2.16 M
|
$984.00 K
|
$1.47 M
|
$1.83 M
|
$21.00 K
|
$21.00 K
|
$14.00 K
|
$15.00 K
|
| Depreciation & Amortization |
$4.07 M
|
$1.38 M
|
$654.00 K
|
$703.00 K
|
$934.00 K
|
$940.00 K
|
$451.00 K
|
$438.00 K
|
$481.89 K
|
$441.00 K
|
| EBITDA |
$3.92 M |
-$57.09 M |
-$28.50 M |
-$24.07 M |
-$27.60 M |
-$22.65 M |
-$22.04 M |
-$24.80 M |
-$15.34 M |
-$15.77 M |
| EBITDA Ratio |
0.14
|
-11.89
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-0.71
|
-10.35
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$11.19 M
|
-$10.92 M
|
$4.21 M
|
-$2.28 M
|
-$7.09 M
|
$2.67 M
|
$2.64 M
|
$888.00 K
|
$672.00 K
|
$1.80 M
|
| Income Before Tax |
-$9.22 M
|
-$60.61 M
|
-$24.95 M
|
-$27.05 M
|
-$30.02 M
|
-$25.45 M
|
-$22.96 M
|
-$24.35 M
|
-$15.84 M
|
-$14.40 M
|
| Income Before Tax Ratio |
-0.32
|
-12.63
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$9.22 M
|
-$60.61 M
|
-$24.95 M
|
-$27.05 M
|
-$30.02 M
|
-$25.45 M
|
-$22.96 M
|
-$24.35 M
|
-$15.84 M
|
-$14.40 M
|
| Net Income Ratio |
-0.32
|
-12.63
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.12 |
-0.94 |
-0.48 |
-0.61 |
-1.8 |
-2.7 |
-3.15 |
-4.05 |
-4.2 |
-4.2 |
| EPS Diluted |
-0.12 |
-0.94 |
-0.48 |
-0.61 |
-1.8 |
-2.7 |
-3.15 |
-4.05 |
-4.2 |
-4.2 |
| Weighted Average Shares Out |
$79.87 M
|
$64.22 M
|
$51.60 M
|
$44.20 M
|
$16.86 M
|
$9.76 M
|
$7.24 M
|
$6.00 M
|
$3.74 M
|
$3.43 M
|
| Weighted Average Shares Out Diluted |
$79.87 M
|
$64.22 M
|
$51.60 M
|
$44.20 M
|
$16.86 M
|
$9.76 M
|
$7.24 M
|
$6.00 M
|
$3.74 M
|
$3.43 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
